Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake
- 26 May 2006
- journal article
- clinical trial
- Published by Wiley in Hematological Oncology
- Vol. 24 (3) , 146-150
- https://doi.org/10.1002/hon.782
Abstract
Positron emission tomography using 2‐[18F]fluoro‐2‐deoxy‐D‐glucose (FDG‐PET) enables quantitative analysis of metabolic activity. This study investigated standardized uptake value (SUV) levels in the different histopathological subtypes of Hodgkin lymphoma (HL). Sixty patients with newly diagnosed HL underwent staging FDG‐PET/CT after lymph node biopsy. Maximum SUV in each patient (SUVmax/total) and in each affected region or organ (SUVmax) were recorded. Mean SUVmax/total was 9.3 g/ml in seven nodular lymphocyte predominance (NLP) patients, 16.3 g/ml in 38 nodular sclerosis (NS) patients, 20.8 g/ml in 11 mixed cellularity (MC) patients, and 19.5 g/ml in four patients with unclassified classical HL (CHL‐NOS), (ANOVA, p = 0.011). Out of 780 sites (600 lymph node regions plus 180 organs), 208 sites were found to be affected with HL. Mean SUVmax was 8.3 g/ml in the 12 sites with NLP, 11.2 g/ml in the 147 sites affected with NS, 14.6 g/ml in the 36 sites with MC, and 13.1 g/ml in the 13 sites with CHL‐NOS (ANOVA, p = 0.002). There is a significant difference in FDG/glucose uptake between the different histopathological subtypes of HL. Copyright © 2006 John Wiley & Sons, Ltd.Keywords
This publication has 24 references indexed in Scilit:
- FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphomaBlood, 2006
- Comparison between 2-deoxy-2-[18F]fluoro-D-Glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphomaMolecular Imaging & Biology, 2004
- Contribution of PET imaging to the initial staging and prognosis of patients with Hodgkin's diseaseAnnals of Oncology, 2004
- FDG-PET in the clinical management of Hodgkin lymphomaCritical Reviews in Oncology/Hematology, 2004
- Positron Emission Tomography for the Staging of Hodgkin's Lymphoma - Increasing the Body of Evidence in Favor of the MethodActa Oncologica, 2002
- Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin's diseaseAnnals of Hematology, 2001
- Whole body positron emission tomography in the treatment of Hodgkin diseaseCancer, 2001
- 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institutionAnnals of Oncology, 2000
- Positron Emission Tomography (PET) for Staging and Evaluation of Response to Treatment in Patients with Hodgkin's DiseaseLeukemia & Lymphoma, 1999
- Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s diseaseAnnals of Oncology, 1998